Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy

AIDS

Volumn 17, Issue SUPPL. 3, 2003, Pages

  Vergne, Laurence ^a   Kane, Coumba Touré ^b   Laurent, Christian ^a   Diakhaté, Ndella ^c   Ngom Gueye, Ndeye Fatou ^c   Gueye, Pape Mandoumbé ^d   Sow, Papa Salif ^c   Faye, Mame Awa ^c   Liégeois, Florian ^a   Ndir, Adama ^e   Lanièce, Isabelle ^a   Peeters, Martine ^a   Ndoye, Ibrahima ^e   Mboup, Souleymane ^b   Delaporte, Eric ^a,f  

^a UNIV MONTPELLIER   (France)

^b Laboratory of Bacteriology and Virology   (Senegal)

^c Thoracic and Cardiovascular Surgery Clinic   (Senegal)

^d Military Hospital   (Senegal)

^e National AIDS Program   (Senegal)

^f UNIVERSITÉ DE MONTPELLIER   (France)

Author keywords

Africa; Antiretroviral therapy; Drug resistance mutations; HIV 1 subtypes

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS RESISTANCE; DEVELOPING COUNTRY; DRUG DOSE REGIMEN; FEMALE; FOLLOW UP; GENE FREQUENCY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENEGAL; SEQUENCE ANALYSIS; SURVIVAL TIME; TUBERCULOSIS; VIRUS LOAD; VIRUS MUTATION; VIRUS STRAIN;

EID: 0041627405     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200317003-00005     Document Type: Article

References (21)

1. Descamps D, Collin G, Letourneur F, Apetrei C, Damond F, Loussert-Ajaka I, et al. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J Virol 1997; 71:8893-8898.
2. Apetrei C, Descamps D, Collin G, Loussert-Ajaka I, Damond F, Duca M, et al. Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility. J Virol 1998; 72:3534-3538.
3. Descamps D, Apetrei C, Collin G, Damond F, Simon F, Brun-Vezinet F. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors. AIDS 1998; 12:1109-1111.
4. Eshleman S, Becker-Pergola G, Deseyve M, Guay LA, Mracna M, Fleming T, et al. Impact of human immunodeficiency virus type 1 (HIV-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent HIV-1 vertical transmission (HIV network for prevention trials 012 study). J Infect Dis 2001; 184:914-917.
5. Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, Toure-Kane C, et al. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 2000; 38:3919-3925.
6. Velasquez-Campoy A, Todd MJ, Vega S, Freire E. Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proc Natl Acad Sci 2001; 98:6062-6067.
7. Perno CF, D'Arminio-Monforte A, Cozzi-Lepri A, Balotta C, Forbici F, Bertoli A, et al. Mutations at codons 10 and 36 of protease region in absence of primary mutations may correlate with virological outcome in naive patients starting a P1-containing HAART regimen. In: Seventh Conference on Retroviruses and Opportunistic Infections, San Franscisco January-February 2000. [Abstract 728].
8. Laurent C, Diakhaté N, Ngom Gueye NF, Toure MA, Sow PS, Faye MA, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS 2002; 16:1363-1370.
9. ANRS. Use of Antiretroviral Drugs in the Management of HIV-infected Persons. October 2000: Updated Recommendations. Paris Agence nationale de recherches sur le SIDA (ANRS) 2000.
10. Thompson J, Higgins D, Gibson T. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucl Acids Res 1994; 22:4673-4680.
11. Shafer RW. http://hivdb.stanford.edu/hiv/. Stanford HIV RT and protease sequence database.
12. Van Kerckhoven I, Fransen K, Peeters M, de Beenhouwer H, Piot P, van der Groen G. Quantification of human immunodeficiency virus in plasma by RNA PCR, viral culture, and p24 antigen detection. J Clin Microbiol 1994; 32:1669-1673.
13. Vergne L, Malonga-Mouellet G, Mistoul I, Mavoungou R, Mansaray H, Peeters M, et al. Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries. J Acquir Immune Defic Syndr 2002; 29:165-168.
14. Adje C, Cheingsong R, Roels TH, Maurice C, Djomand G, Verbiest W, et al. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 2000; 26:501-506.
15. Harries AD, Nyangulu DS, Hargreaves NJ, Kaluwa O, Salaniponi FM. Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet 2001; 358:410-414.
16. Weidle PJ, Kityo CS, Mugyenyi P, Downing R, Kebba A, Pieniazek D, et al. Resistance to antiretroviral therapy among patients in Uganda. J Acquir Immune Defic Syndr 2001; 26:495-500.
17. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269:696-699.
18. Picard V, Angelini E, Maillard A, Race E, Clavel F, Chene G, et al. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine. J Infect Dis 2001; 184:781-784.
19. Coakley EP, Gillis JM, Hammer SM. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS 2000; 14:F9-F15.
20. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999; 354:729-733.
21. Frater A, Beardall A, Ariyoshi K, Churchill D, Galpin S, Clarke JR, et al. Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients. AIDS 2001; 15:1493-1502.